Literature DB >> 10932225

Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Z Y Yang1, H J Duckers, N J Sullivan, A Sanchez, E G Nabel, G J Nabel.   

Abstract

Here we defined the main viral determinant of Ebola virus pathogenicity; synthesis of the virion glycoprotein (GP) of Ebola virus Zaire induced cytotoxic effects in human endothelial cells in vitro and in vivo. This effect mapped to a serine-threonine-rich, mucin-like domain of this type I transmembrane glycoprotein, one of seven gene products of the virus. Gene transfer of GP into explanted human or porcine blood vessels caused massive endothelial cell loss within 48 hours that led to a substantial increase in vascular permeability. Deletion of the mucin-like region of GP abolished these effects without affecting protein expression or function. GP derived from the Reston strain of virus, which causes disease in nonhuman primates but not in man, did not disrupt the vasculature of human blood vessels. In contrast, the Zaire GP induced endothelial cell disruption and cytotoxicity in both nonhuman primate and human blood vessels, and the mucin domain was required for this effect. These findings indicate that GP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10932225     DOI: 10.1038/78645

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  188 in total

1.  Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Authors:  Graham Simmons; Rouven J Wool-Lewis; Frédéric Baribaud; Robert C Netter; Paul Bates
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Infection and activation of monocytes by Marburg and Ebola viruses.

Authors:  U Ströher; E West; H Bugany; H D Klenk; H J Schnittler; H Feldmann
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Ebola virus VP40-induced particle formation and association with the lipid bilayer.

Authors:  L D Jasenosky; G Neumann; I Lukashevich; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Authors:  Gopi S Mohan; Ling Ye; Wenfang Li; Ana Monteiro; Xiaoqian Lin; Bishu Sapkota; Brian P Pollack; Richard W Compans; Chinglai Yang
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

5.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

6.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 7.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

8.  Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus.

Authors:  Angela J Sanchez; Martin J Vincent; Stuart T Nichol
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 9.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

10.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.